HomeCompareAMFFX vs JNJ

AMFFX vs JNJ: Dividend Comparison 2026

AMFFX yields 7.66% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMFFX wins by $13.2K in total portfolio value
10 years
AMFFX
AMFFX
● Live price
7.66%
Share price
$58.11
Annual div
$4.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.2K
Annual income
$1,244.41
Full AMFFX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — AMFFX vs JNJ

📍 AMFFX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMFFXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMFFX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMFFX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMFFX
Annual income on $10K today (after 15% tax)
$651.05/yr
After 10yr DRIP, annual income (after tax)
$1,057.75/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, AMFFX beats the other by $354.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMFFX + JNJ for your $10,000?

AMFFX: 50%JNJ: 50%
100% JNJ50/50100% AMFFX
Portfolio after 10yr
$26.6K
Annual income
$1,036.10/yr
Blended yield
3.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AMFFX
No analyst data
Altman Z
30.6
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMFFX buys
0
JNJ buys
0
No recent congressional trades found for AMFFX or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMFFXJNJ
Forward yield7.66%3.36%
Annual dividend / share$4.45$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$33.2K$20.0K
Annual income after 10y$1,244.41$827.78
Total dividends collected$10.1K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AMFFX vs JNJ ($10,000, DRIP)

YearAMFFX PortfolioAMFFX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,466$765.94$10,676$355.77+$790.00AMFFX
2$13,089$820.77$11,407$389.39+$1.7KAMFFX
3$14,881$875.68$12,198$426.53+$2.7KAMFFX
4$16,853$930.43$13,056$467.62+$3.8KAMFFX
5$19,018$984.80$13,987$513.12+$5.0KAMFFX
6$21,388$1,038.58$14,998$563.56+$6.4KAMFFX
7$23,977$1,091.59$16,098$619.52+$7.9KAMFFX
8$26,799$1,143.66$17,295$681.69+$9.5KAMFFX
9$29,869$1,194.64$18,599$750.82+$11.3KAMFFX
10$33,204$1,244.41$20,022$827.78+$13.2KAMFFX

AMFFX vs JNJ: Complete Analysis 2026

AMFFXStock

The investment seeks current income, growth of capital and conservation of principal. The fund invests primarily in common stocks of companies that are likely to participate in the growth of the American economy and whose dividends appear to be sustainable. It invests primarily in securities of issuers domiciled in the United States and Canada. The fund may also invest in bonds and other debt securities, including those issued by the U.S. government and by federal agencies and instrumentalities.

Full AMFFX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this AMFFX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMFFX vs SCHDAMFFX vs JEPIAMFFX vs OAMFFX vs KOAMFFX vs MAINAMFFX vs ABBVAMFFX vs MRKAMFFX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.